Device Brand Names Unnecessary In Open Payments Database, Industry Says
This article was originally published in The Gray Sheet
Listing device brand names as part of physician payment disclosures to the Open Payments database would be difficult, and not meaningful, AdvaMed suggests. CMS has proposed updating its regulations to require device brand names to be included in Sunshine Act disclosures.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.